Clinicians
Clinicians Home Consult Request Knowledge Base Education Catalog Centers Of Excellence
Individuals & Families
Guidance Knowledge Base Resources
Our Tools
Clozapine Dose Planner LAI Conversion Tool LAI Explorer
About Us
Contact

Search for:

∕
Knowledge Base (Clinicians)
∕
Long-acting Injectables

Tag: Long-acting Injectables

Knowledge Base (Clinicians)

94 result(s) found.

How do you treat akathisia from treatment with long-acting injectable antipsychotics (LAIs)?
Guide to Long-Acting Medications for Providers and Organizations – Reserved for Treatment-Resistant cases?
Long-acting injection antipsychotic medications in the management of schizophrenia (excerpt from APA Clinical Practice Guideline)
Aspiration in injections: Should we continue or abandon the practice?
What is post-injection delirium sedation syndrome (PDSS) that is associated with the olanzapine long-acting injectable (Zyprexa Relprevv)?
Long-Acting Injectables: Pharmacological Information – LAI Table of Considerations
When prescribing, what should I consider regarding doses of antipsychotic medications, oral or long-acting injectable medications?
What should clinicians know about risperidone or Risperdal Consta (“Consta”) (risperidone microspheres LAI)?
What should clinicians know about Abilify Maintena (aripiprazole monohydrate LAI)?
What should clinicians know about Perseris (risperidone subcutaneous LAI)?
What should clinicians know about Aristada Initio (aripiprazole lauroxil LAI)?
What should clinicians know about Aristada (aripiprazole lauroxil LAI)?
Long-Acting Injectable Center of Excellence
What should clinicians know about haloperidol decanoate (“Haldol Dec”)?
What should clinicians know about fluphenazine decanoate (“Prolixin Dec”)?
What should clinicians know about Invega Trinza (paliperidone palmitate 12-week LAI)?
What long-acting injectable (LAI) antipsychotic medications are available in the U.S.?
What should a provider consider when administering long-acting injectable (LAI) antipsychotics?
What should I consider if a patient is taking an antipsychotic medication and abusing substances?
Are there patient handouts regarding long-acting injectable (LAI) antipsychotic medications?
What should I consider and how do I change or switch a patient from a different long acting injectable medication (LAI) to Abilify Maintena?
What should clinicians know about Invega Sustenna (paliperidone palmitate LAI)?
What mistakes should providers be aware of when prescribing and administering long-acting injectables (LAIs)?
What should providers consider when talking to patients and their families about starting a long-acting injectable (LAI) antipsychotic?
What are important considerations for the use of long-acting injectable (LAI) antipsychotic medications in first-episode psychosis patients?
What is known about long acting injectable (LAI) antipsychotic medications in the treatment of schizophrenia or bipolar disorder?
What should clinicians who work with American Indian/Alaska Native people consider when prescribing long-acting injectable (LAI) antipsychotics?
What is known about therapeutic drug monitoring (TDM) for antipsychotic medications?
Is there anything that can be done if a patient experiences sedation as a side effect after a long-acting injectable (LAI) deltoid injection?
How do I transition a patient from risperidone oral to paliperidone palmitate (Invega Sustenna) long-acting injectable (LAI)?
What are clinical situations where the use of an oral antipsychotic together with a long-acting injectable (LAI) antipsychotics may make sense?
What are clinical indications for the use of long-acting injectable (LAI) antipsychotics?
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
What is shared decision making and how does it apply to using long-acting injectables (LAIs)?
What can be done if a LAI medication becomes less effective part way through the inter-injection interval?
In treating Indian American populations with SMI, are there any unique factors that must be considered?
What are clinical considerations for giving LAIs during the COVID-19 public health emergency?
Can risperidone, paliperidone (Invega) or first generation antipsychotic medications cause elevated or high prolactin levels, and related side effects such as sexual dysfunction, gynecomastia or galactorrhea?
What should I consider and how do I change or switch a patient from a different long acting injectable (LAI) antipsychotic medication to Aristada?
Are antipsychotic drug dose equivalents derived using the Defined Daily Doses (DDD) method useful in clinical practice?
Evaluating patient satisfaction with pharmacist-administered long-acting injectable antipsychotics in the community pharmacy
What should I consider and how do I change or switch a patient from a different long-acting injectable medication (LAI) to Invega Sustenna (paliperidone palmitate)?
What should clinicians know about Zyprexa Relprevv (olanzapine for extended release injectable suspension)?
How can I manage extrapyramidal side effects from long-acting injectable antipsychotics (LAIs)?
How do I treat an acute dystonic reaction (ADR)?
When should you offer a long-acting injectable (LAI) for first-episode patients?
What are dose conversions from oral to injectable for the long-acting injectable (LAI) antipsychotic medications available in the U.S.?
Long-acting injectable antipsychotics (LAIs) use for older adults
How are prolactin levels impacted by long-acting injectable (LAI) antipsychotic medications?
What is recommended for handling waste associated with administration of long-acting injectable antipsychotics (LAIs)?
How do I switch a patient treated with LAI to Risperdal Consta (risperidone microspheres)?
Atypical Injectable Antipsychotics for Schizophrenia or Bipolar Disorder: A Review of Clinical Effectiveness and Cost-Effectiveness
Should clinicians massage the injection site when giving long-acting injectable antipsychotic (LAI) injections?
Clozapine & LAI Virtual Forum – August 2020 (Video) – Clozapine hematologic monitoring and COVID-19
Clozapine & LAI Virtual Forum – September 2020 (Video) – Antipsychotic conversion to LAIs
Clozapine & LAI Virtual Forum – October 2020 (Video) – Understanding and mitigating clozapine-induced myocarditis
What do APA’s Schizophrenia Treatment Guidelines say about long-acting injectable antipsychotics?
Clozapine & LAI Virtual Forum – November 2020 (Video) – Early psychosis and LAIs
In what states may pharmacists legally administer long-acting injectable antipsychotic medications?
Clozapine & LAI Virtual Forum – January 2021 (Video) – Strategies for managing breakthrough symptoms for patients on LAIs
Antipsychotic Receptor Binding Properties
Clozapine & LAI Virtual Forum – March 2021 (Video) – LAIs during COVID-19
Clozapine & LAI Virtual Forum – May 2021 (Video) – Interpreting plasma levels for patients on LAIs
Clozapine & LAI Virtual Forum – July 2021 (Video) – Is there a role for First-Generation Antipsychotic (FGA) LAIs?
Clozapine & LAI Virtual Forum – September 2021 (Video) – Talking to patients and family members about LAIs
Guidance for Missed Maintenance Doses for Long Acting Injectable Antipsychotics
What should clinicians know about Invega Hafyera (paliperidone palmitate 6-month LAI)?
Long Acting Injectable (LAI) Antipsychotic Use During Pregnancy
Clozapine & LAI Virtual Forum – November 2021 (Video) – The role of LAIs in crisis prevention and response
Talking to Individuals and Families About Long-Acting Injectables
Clozapine & LAI Virtual Forum – February 2022 (Video) – LAI antipsychotics and oral augmentation and overlap
What is tardive dyskinesia (TD)?
Clozapine & LAI Virtual Forum – May 2022 (Video) – Long-Acting Injectable (LAI) Antipsychotics and Antipsychotic Polypharmacy (APP)
Antipsychotics and heat-related illnesses
Clozapine & LAI Virtual Forum – August 2022 (Video) – LAI Discontinuation
Video: Intramuscular (IM) Injection of Long-acting Injectables into Deltoid Site
Video: Intramuscular (IM) Injection of Long-acting Injectables into Ventral Gluteal (or Ventrogluteal) Site
Video: Intramuscular (IM) Injection of Long-acting Injectables into Dorsal Gluteal (or Dorsogluteal) Site
Video: Subcutaneous (SC) Injection of Long-acting Injectables into Abdominal Site
Clozapine & LAI Virtual Forum – October 2022 (Video) – LAIs and troubleshooting insurance coverage
Clozapine & LAI Virtual Forum – December 2022 (Video) – Pharmacist administration of LAIs
Video: Subcutaneous (SC) Injection of Long-acting Injectables into Lateral Aspect of Upper Arm
Clozapine & LAI Virtual Forum – April 2023 (Video) – Physical Health / Cardiometabolic Monitoring for Patients on LAIs
What should clinicians know about Uzedy (risperidone subcutaneous LAI)?
What should clinicians know about Abilify Asimtufii (aripiprazole LAI)?
Clozapine & LAI Virtual Forum – June 2023 (Video) – Update on the Long-Acting Injectable Antipsychotic Medications
Clozapine & LAI Virtual Forum – September 2023 (Video) – Making Sense of the Long-Acting Injectable (LAI) Antipsychotic Medication Research
Clozapine & LAI Virtual Forum – October 2023 (Video) -Debrief on New Long-acting Injectable Antipsychotic Medications (LAIs)
Clozapine & LAI Virtual Forum – December 2023 (Video) – Comparing Risperidone and Paliperidone LAI Products
Clozapine & LAI Virtual Forum – February 2024 (Video) – Comparing Aripiprazole LAI Products
What should clinicians know about Brixadi (Subutex)?
What should clinicians know about Vivitrol (Naltrexone)?
What should clinicians know about Sublocade (Suboxone)?
Clozapine & LAI Virtual Forum – April 2024 (Video) – LAIs and VMAT2 Inhibitors

Administered by

About SMI Adviser

Mission Statement

Our mission is to advance the use of a person-centered approach to care that ensures people who have SMI find the treatment and support they need.

For clinicians, we offer access to education, data, and consultations so you can make evidence-based treatment decisions.

For patients, families, friends, people who have questions, or people who care for someone with SMI, we offer access to resources and answers from a national network of experts.

Grant Statement

Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.

Terms & Privacy
Copyright

Sitemap

Clinicians
Individuals & Families
About
Contact

SMI Adviser is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of the website's resources, please call us at 202-559-3900 for assistance.

Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.

© 2025 American Psychiatric Association. All rights reserved.